Volition signs an exclusive license and supply agreement with Heska

The $28 million deal will allow Volition to distribute the Nu.Q Vet cancer screening test worldwide.

VolitionRx Limited (Volition) – a multinational epigenetics company announced that it has signed an exclusive worldwide supply and licensing agreement with Heska Corporation (Heska) – a global provider of advanced veterinary diagnostics. Through this new agreement, Heska will receive exclusive worldwide rights to sell Volition Nu.Q Vet Cancer Screening Test. According to the release, in exchange, Volition will receive an upfront payment of $10 million upon signing and up to $18 million based on significant short-to-mid-term achievement.1

“We are delighted to announce this agreement with Heska, a company dedicated to developing the next generation of rapid and highly affordable point-of-care diagnostics for companion animals,” said Tom Butera, DVM, Managing Director of Volition Veterinary. Diagnostics Development. LLC, in the release.1

“We estimate that the total addressable market worldwide for canine and feline cancer screening and monitoring is approximately $11 billion and growing. As such, we want to make our cancer screening test Nu.Q Vet cancer as accessible as possible to veterinarians around the world, ensuring cancer is detected earlier and improving outcomes for pets and pet owners,” he explained

According to the release, Volition’s Nu.Q Vet cancer screening test will operate on Heska’s proprietary Element i+ Immunodiagnostic Analyzer point-of-care platform.1 Through this agreement, veterinarians will be able to screen pets for some of the most common cancers while providing crucial information to customers.

“The accurate, affordable, rapid and non-invasive Nu.Q Vet cancer screening test is exactly such an innovation and a perfect addition to our Heska test menu, which we believe is now the most comprehensive point , differentiated and forward-thinking of a stack of care diagnostic solutions available to pet healthcare professionals and pet families,” said Kevin Wilson, CEO and President of Heska.

“With the new Heska Nu.Q Vet cancer screening test, millions of pets will have access to critical cancer screening and monitoring instantly, and at the point of care, to catch, treat and promote recovery from cancers earlier and with much better health outcomes and peace of mind,” he continued in the statement.


Volition signs an exclusive $28 million license and supply agreement with Heska Corporation to distribute the Nu.Q® veterinary cancer screening test at the point of care. Press release. VolitionRx Limited. March 29, 2022. Accessed March 30, 2022. https://www.prnewswire.com/news-releases/volition-signs-exclusive-28-million-license-and-supply-agreement-with-heska-corporation-to- distribute-nuq-vet-cancer-screening-test-at-the-point-of-care-301512651.html